Injectable Hyaluronic Acid for Wrinkles

AP
Overseen ByAndrea Pacheco
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to evaluate the effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid in real-world settings for treating mild-to-moderate facial aging. The focus is on improving volume loss, fine lines, and skin laxity. Suitable candidates will have noticeable facial aging but no facial injections or surgeries in the past year. Participants must adhere to a specific skincare routine and avoid other facial treatments during the study. As a Phase 4 trial, this study involves an FDA-approved treatment, allowing participants to benefit from a proven therapy while contributing to broader understanding.

Do I have to stop taking my current medications for the trial?

The trial does not specify if you need to stop taking your current medications. However, you cannot use certain treatments like injectable fillers, neuromodulators, or systemic retinoids close to the study period. It's best to discuss your specific medications with the trial investigator.

What is the safety track record for Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid?

Research shows that Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) is safe for treating facial aging issues like wrinkles and volume loss. Studies have demonstrated that this HA gel has a strong safety record. Most people tolerate it well, and the U.S. FDA has approved it, indicating it has passed thorough testing and review.

As with any skin injection, minor side effects like redness or swelling may occur, but serious problems are rare. The safety results for this HA gel align with those of other products. Previous studies have shown impressive safety outcomes, with few adverse events reported. This suggests that the treatment is generally safe for people.12345

Why are researchers enthusiastic about this study treatment?

Unlike most treatments for wrinkles that often involve creams or surgical procedures, the Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid is an injectable solution that directly adds volume and hydration to the skin. This approach can lead to more immediate and noticeable results in reducing wrinkles, compared to topical treatments which may take longer to show effects. Researchers are particularly excited because the treatment uses a high-quality hyaluronic acid, which is known for its ability to retain moisture, potentially offering a more natural and youthful appearance. The injectable form also allows for precise targeting of specific areas, making it a versatile option for various types of facial wrinkles.

What is the effectiveness track record for Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid for facial aging?

Research has shown that Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid effectively improves facial wrinkles and restores volume. Studies have demonstrated that this treatment can correct moderate to severe facial wrinkles and folds, such as nasolabial folds around the nose and mouth. In a recent trial, 94% of users reported that MagIQ works well with other fillers. Additionally, participants noticed significant improvements in wrinkles, skin texture, and overall skin appearance after 12 weeks of use. This FDA-approved treatment underscores its safety and effectiveness for enhancing facial appearance.12467

Are You a Good Fit for This Trial?

This trial is for adults aged 30 to 75 with mild-to-moderate facial aging, such as volume loss or sagging skin. Participants must be in good health, willing to follow study rules and skincare routines, and not start new facial treatments during the study. Women of childbearing age need a negative pregnancy test and must use contraception.

Inclusion Criteria

I am between 30 and 75 years old.
2. Fitzpatrick skin types I-VI.
6. In good general health as determined by the investigator based on medical history and clinical judgment.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive up to two treatments with Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid gel

60 days
2 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including standardized 2D photography and VISIA photography assessments

60 days
2 visits (in-person) at Day 14 and Day 60

What Are the Treatments Tested in This Trial?

Interventions

  • Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid

Trial Overview

The study tests Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid gel for treating wrinkles, sagging skin, and lost facial volume. The treatment is given by standard injection methods over a period of 60 days to see how well it works in real-world settings.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Obagi® Saypha® MagIQ™ Injectable Hyaluronic AcidExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Goldman, Butterwick, Fitzpatrick and Groff

Lead Sponsor

Trials
32
Recruited
660+

Obagi

Collaborator

Citations

SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED)

saypha MagIQ is indicated for injection into the mid and deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) ...

Assess Injectable Hyaluronic Acid Gel for the Treatment of ...

Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate ...

Obagi Medical Unveils New Clinical Data on Skincare ...

The study indicated significant improvements in wrinkles, hyperpigmentation, and overall skin radiance after 12 weeks of use. How does Obagi ...

Obagi Medical unveils SCALE data on MagIQ filler

The ALOHA interim data show 94% of injectors believe MagIQ complements existing fillers, with 43% of patients also evaluating Obagi skincare. NU ...

Obagi Medical Shares New Clinical Data on ...

This pivotal, randomized, multicenter trial compared the effectiveness and safety of two hyaluronic acid fillers for midface volume restoration ...

The Safety Profile of a Portfolio of Hyaluronic Acid-Based Soft ...

Safety outcomes were consistent across formulations and between the legacy Princess and current saypha products. Overall, the saypha HA filler ...

Waldencast Announces FDA Approval of Obagi® saypha® ...

“Obagi ® saypha® MagIQ™ sets a new standard in HA dermal fillers in the U.S., offering our professionals and patients proven innovation with a ...